The FGFR2 fusion necessitates the involvement of the downstream effector Mek1/2, indicating the potential clinical efficacy of dual blockade targeting FGFR2 and MEK1/2 in patients with intrahepatic cholangiocarcinoma (ICC) [63]. The gene discussed is MAP2K1; the disease is intrahepatic cholangiocarcinoma.